Latest Insider Transactions at Intra Cellular Therapies, Inc. (ITCI)
This section provides a real-time view of insider transactions for Intra Cellular Therapies, Inc. (ITCI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Intra-Cellular Therapies, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Intra-Cellular Therapies, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 10
2025
|
Michael Halstead President |
SELL
Payment of exercise price or tax liability
|
Direct |
3,757
-14.99%
|
$492,167
$131.24 P/Share
|
|
Mar 10
2025
|
Michael Halstead President |
BUY
Exercise of conversion of derivative security
|
Direct |
7,345
+22.66%
|
-
|
|
Mar 10
2025
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,116
-5.57%
|
$408,196
$131.24 P/Share
|
|
Mar 10
2025
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,345
+11.61%
|
-
|
|
Mar 10
2025
|
Sharon Mates Chairman and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,129
-0.88%
|
$1,326,899
$131.24 P/Share
|
|
Mar 10
2025
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,566
+1.76%
|
-
|
|
Mar 10
2025
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,116
-6.77%
|
$408,196
$131.24 P/Share
|
|
Mar 10
2025
|
Suresh K. Durgam EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,345
+13.76%
|
-
|
|
Mar 06
2025
|
Michael Halstead President |
SELL
Payment of exercise price or tax liability
|
Direct |
6,718
-27.49%
|
$880,058
$131.19 P/Share
|
|
Mar 06
2025
|
Michael Halstead President |
BUY
Exercise of conversion of derivative security
|
Direct |
13,133
+34.96%
|
-
|
|
Mar 06
2025
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,572
-10.29%
|
$729,932
$131.19 P/Share
|
|
Mar 06
2025
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,133
+19.52%
|
-
|
|
Mar 06
2025
|
Sharon Mates Chairman and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
19,848
-1.73%
|
$2,600,088
$131.19 P/Share
|
|
Mar 06
2025
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
40,712
+3.43%
|
-
|
|
Mar 06
2025
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,572
-12.59%
|
$729,932
$131.19 P/Share
|
|
Mar 06
2025
|
Suresh K. Durgam EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,133
+22.88%
|
-
|
|
Mar 01
2025
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,709
-10.65%
|
$474,752
$128.2 P/Share
|
|
Mar 01
2025
|
Suresh K. Durgam EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,742
+20.06%
|
-
|
|
Mar 01
2025
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,709
-8.29%
|
$474,752
$128.2 P/Share
|
|
Mar 01
2025
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,742
+16.35%
|
-
|
|
Mar 01
2025
|
Michael Halstead President |
SELL
Payment of exercise price or tax liability
|
Direct |
6,261
-35.64%
|
$801,408
$128.2 P/Share
|
|
Mar 01
2025
|
Michael Halstead President |
BUY
Exercise of conversion of derivative security
|
Direct |
12,239
+41.07%
|
-
|
|
Mar 01
2025
|
Sharon Mates Chairman and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
16,978
-1.51%
|
$2,173,184
$128.2 P/Share
|
|
Mar 01
2025
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
34,969
+3.03%
|
-
|
|
Feb 24
2025
|
Joel S Marcus |
BUY
Exercise of conversion of derivative security
|
Direct |
7,009
+12.69%
|
$441,567
$63.79 P/Share
|
|
Jan 31
2025
|
Mark Neumann EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,729
-11.61%
|
$600,583
$127.0 P/Share
|
|
Jan 31
2025
|
Mark Neumann EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,017
+21.3%
|
-
|
|
Jan 31
2025
|
Michael Halstead President |
SELL
Payment of exercise price or tax liability
|
Direct |
5,691
-51.66%
|
$722,757
$127.0 P/Share
|
|
Jan 31
2025
|
Michael Halstead President |
BUY
Grant, award, or other acquisition
|
Direct |
11,017
+50.0%
|
-
|
|
Jan 31
2025
|
Sharon Mates Chairman and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
15,233
-1.38%
|
$1,934,591
$127.0 P/Share
|
|
Jan 31
2025
|
Sharon Mates Chairman and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
30,847
+2.72%
|
-
|
|
Jan 31
2025
|
Suresh K. Durgam EVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,730
-15.35%
|
$600,710
$127.0 P/Share
|
|
Jan 31
2025
|
Suresh K. Durgam EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,017
+26.33%
|
-
|
|
Dec 31
2024
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
215
+0.16%
|
$17,845
$83.52 P/Share
|
|
Dec 05
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
51,697
-2.31%
|
$4,342,548
$84.38 P/Share
|
|
Dec 05
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
51,697
+4.4%
|
$620,364
$12.73 P/Share
|
|
Dec 04
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
51,000
-2.3%
|
$4,335,000
$85.81 P/Share
|
|
Dec 04
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
51,000
+4.35%
|
$612,000
$12.73 P/Share
|
|
Nov 13
2024
|
Michael Halstead President |
SELL
Open market or private sale
|
Direct |
18,714
-85.72%
|
$1,646,832
$88.54 P/Share
|
|
Nov 13
2024
|
Michael Halstead President |
BUY
Exercise of conversion of derivative security
|
Direct |
18,714
+50.0%
|
$673,704
$36.89 P/Share
|
|
Nov 12
2024
|
Michael Halstead President |
SELL
Open market or private sale
|
Direct |
22,869
-81.61%
|
$2,035,341
$89.75 P/Share
|
|
Nov 12
2024
|
Michael Halstead President |
BUY
Exercise of conversion of derivative security
|
Direct |
22,869
+50.0%
|
$525,987
$23.94 P/Share
|
|
Sep 30
2024
|
Rory B Riggs |
BUY
Grant, award, or other acquisition
|
Direct |
246
+0.21%
|
$17,958
$73.17 P/Share
|
|
Aug 30
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
34,396
-1.56%
|
$2,510,908
$73.03 P/Share
|
|
Aug 30
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
34,396
+3.02%
|
$412,752
$12.73 P/Share
|
|
Aug 29
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
35,604
-1.62%
|
$2,563,488
$72.85 P/Share
|
|
Aug 29
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
35,604
+3.12%
|
$427,248
$12.73 P/Share
|
|
Aug 28
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
32,699
-1.48%
|
$2,387,027
$73.22 P/Share
|
|
Aug 28
2024
|
Sharon Mates Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
32,699
+2.88%
|
$555,883
$17.57 P/Share
|
|
Aug 27
2024
|
Sharon Mates Chairman and CEO |
SELL
Open market or private sale
|
Direct |
40,513
-1.84%
|
$2,957,449
$73.63 P/Share
|